← Back to all trials
Active Not Recruiting
NCT06557850
A Trial Investigating Lu AG22515 in Adult Participants With Moderate-to-Severe Thyroid Eye Disease
Conditions: Thyroid Eye Disease
Sex: All
Ages: 18 Years – N/A
Healthy volunteers: No
Phase: PHASE1
Enrollment: 20
Sponsor: H. Lundbeck A/S
Location: University Clinical Center of The Republic Of Srpska Banja Luka Republika Srpska
Summary
This trial will evaluate the effects of Lu AG22515 in adult men and women with moderate-to-severe thyroid eye disease (TED). TED is an autoimmune condition closely related to Graves' Disease.
In people with TED, the healthy tissue behind and around the eye becomes inflamed and swollen. One of the key symptoms of TED is proptosis (bulging eyes). The main goal of this trial is to learn whether treatment with Lu AG22515 improves proptosis in participants with moderate-to-severe TED.
Eligibility Criteria
Inclusion Criteria:
* The participant has Graves' disease associated Thyroid Eye Disease (TED) symptoms characterized by:
* ophthalmologic symptom onset \3 weeks prior to the Screening Visit of selenium. Inactivated/killed/RNA-based vaccinations are allowed provided they are not administered within 5 days before/after any investigational medicinal product (IMP) trial visits.
Source: ClinicalTrials.gov (NCT06557850). StuddyBuddy aggregates publicly available trial information.
